Patient description: The patients is a 25-year-old G1 P1 pregnant woman who is 24W3D gestational old who developed a sudden unset of fever and chills, accompany with nausea and vomiting. She also complains of dysuria, urgency and frequency. She also reports some severe pain in the flank. Her vital signs are: T = 39.7ºC, P = 117, R = 20, and BP = 113/74 mm Hg. Physical examination reveals tenderness on palpation of both costovertebral angles. She has no history of recurrent UTI prior to her pregnancy or any other underlying disease. The urine culture showed Gram-negative rod-shaped bacterial cells, leukocytes, and leukocyte casts. The blood culture is negative. A CBC shows Hb 12.9 g/dL, Hct 39%, MCV 76 fL, WBC count 14,120/µL.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  West Nile Neuroinvasive Disease West Nile Virus Infection Encephalitis Meningitis Acute Flaccid Paralysis West Nile Fever Provide written informed consent 2. Be >=18 years of age at the time of enrollment 3. Have West Nile Fever defined as: 1. temperature >38°C, headache, AND 2. positive diagnostic test for WNV Ribonucleic acid or Immunoglobulin M with serum or cerebrospinal fluid (CSF) OR have West Nile Neuroinvasive Disease (includes neurological signs and/or symptoms of West Nile meningitis, encephalitis, and/or acute flaccid paralysis), defined as: • West Nile encephalitis (must meet a and b below) 1. Encephalopathy (depressed or altered level of consciousness, lethargy, or personality change lasting 24 hours) 2. CSF pleocytosis >=5 cells/mm^3 AND/OR • West Nile meningitis (must meet c and d) 3. Clinical signs of meningeal inflammation, including nuchal rigidity, Kernig or Brudzinski sign, photophobia, or phonophobia 4. CSF pleocytosis >=5 cells/mm^3 AND/OR • Acute flaccid paralysis (must meet e and f) 5. Acute onset of limb weakness with marked progression over 48 hours 6. Two or more of the following conditions asymmetry to weakness areflexia or hyporeflexia of affected limb(s) absence of pain, paresthesia, or numbness in affected limb(s) CSF pleocytosis >=5 cells/mm^3 CSF elevated protein levels (4.5 g/L) electrodiagnostic studies consistent with an anterior horn cell process or abnormal increased signal in the anterior gray matter as documented by spinal cord magnetic resonance imaging 4. Have epidemiological factors consistent with West Nile Virus infection (must meet criterion a or b below): 1. Appropriate time of year for West Nile Virus transmission in region 2. Travel history to a region where West Nile Virus is active 5. Develop signs and/or symptoms within 14 days before study enrollment. 6. If female of childbearing potential or male and in a sexual relationship with a female of childbearing potential, agree (or have partner agree) to practice abstinence or use 2 of the following methods of contraception for 120 days (approximately 4 months) after study drug administration: 1. Oral contraceptives, or other form of hormonal birth control including hormonal vaginal rings or transdermal patches 2. An intrauterine device 3. Barrier contraception (condom) with a spermicide (i.e., female subject ensures use by male partner[s]) 4. Any other equivalent method of contraception (as judged by the investigator)